Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Marignani

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Journal of Viral Hepatitis|April 12, 2019
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infectionRomina Salpini, Arianna Battisti, Luna Colagrossi, et al.
Microorganisms|November 19, 2020
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in ItalyMarco Canzoni, Massimo Marignani, Maria Laura Sorgi, et al.
BMC Gastroenterology|November 20, 2012
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1bAdriano M Pellicelli, Mario Romano, Tommaso Stroffolini, et al.
Gut and Liver|April 12, 2019
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic PatientsAdriano Pellicelli, Vincenzo Messina, Valerio Giannelli, et al.
Emerging Microbes & Infections|June 8, 2023
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategiesLorenzo Piermatteo, Stefano D'Anna, Ada Bertoli, et al.
Annals of Hepatology|June 14, 2014
Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinomaAdriano M Pellicelli, Pascal Vignally, Vincenzo Messina, et al.
Viruses|February 28, 2020
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in VitroRomina Salpini, Lorenzo Piermatteo, Arianna Battisti, et al.
Drugs in Context|January 7, 2021
Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice studyRodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, et al.
Hepatology (Baltimore, Md.)|November 25, 2014
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppressionRomina Salpini, Luna Colagrossi, Maria Concetta Bellocchi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 9, 2023
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replicationRomina Salpini, Lorenzo Piermatteo, Giulia Torre, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Journal of Viral Hepatitis|April 12, 2019
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infectionRomina Salpini, Arianna Battisti, Luna Colagrossi, et al.
Microorganisms|November 19, 2020
Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in ItalyMarco Canzoni, Massimo Marignani, Maria Laura Sorgi, et al.
BMC Gastroenterology|November 20, 2012
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1bAdriano M Pellicelli, Mario Romano, Tommaso Stroffolini, et al.
Gut and Liver|April 12, 2019
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic PatientsAdriano Pellicelli, Vincenzo Messina, Valerio Giannelli, et al.
Emerging Microbes & Infections|June 8, 2023
Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategiesLorenzo Piermatteo, Stefano D'Anna, Ada Bertoli, et al.
Annals of Hepatology|June 14, 2014
Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinomaAdriano M Pellicelli, Pascal Vignally, Vincenzo Messina, et al.
Viruses|February 28, 2020
A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in VitroRomina Salpini, Lorenzo Piermatteo, Arianna Battisti, et al.
Drugs in Context|January 7, 2021
Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice studyRodolfo Sacco, Vincenzo Messina, Umberto Vespasiani Gentilucci, et al.
Hepatology (Baltimore, Md.)|November 25, 2014
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppressionRomina Salpini, Luna Colagrossi, Maria Concetta Bellocchi, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 9, 2023
Prevalence of hepatitis D virus infection in Central Italy has remained stable across the last 2 decades with dominance of subgenotypes 1 and characterized by elevated viral replicationRomina Salpini, Lorenzo Piermatteo, Giulia Torre, et al.
Pageof 8